# Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer

> **NCT01214291** · PHASE3 · WITHDRAWN · sponsor: **GTx**

## Conditions studied

- Risk of Bone Fracture Occurrences

## Interventions

- **DRUG:** Toremifene

## Key facts

- **NCT ID:** NCT01214291
- **Lead sponsor:** GTx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-03
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** cost of conducting the study and increased burden on the clinical trial professionals make it impossible for us to proceed with the development of the drug.
- **Last updated:** 2013-11-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01214291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01214291, "Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01214291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*